SAB Biotherapeutics, Inc. - Common Stock (SABS)
1.1900
-0.0600 (-4.80%)
NASDAQ · Last Trade: Apr 3rd, 3:52 PM EDT

SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.
Via Benzinga · January 28, 2025

Via Benzinga · January 28, 2025

Via Benzinga · January 28, 2025

Via Benzinga · October 18, 2024

SABS stock results show that SAB Biotherapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 9, 2024

Via Benzinga · June 20, 2024

Via Benzinga · June 19, 2024

Via Benzinga · June 18, 2024

SABS stock results show that SAB Biotherapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 21, 2024

Shares of Applied Therapeutics, Inc.
Via Benzinga · January 5, 2024

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Via Benzinga · January 3, 2024

The Dow Jones closed higher by more than 500 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · December 1, 2023

SAB Biotherapeutics Inc (NASDAQ: SABS) announced that the first HUMAN trial participants (Fully HUman anti-thymocyte biologic in a first-in-MAN clinical study) have been dosed in Australia.
Via Benzinga · November 29, 2023

Via Benzinga · November 16, 2023

Via Benzinga · October 24, 2023

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 100 points on Thursday. The Dow traded down 0.43% to 33,520.17 while the NASDAQ fell 0.75% to 13,214.04. The S&P 500 also fell, dropping, 0.62% to 4,287.95.
Via Benzinga · October 19, 2023

Via Benzinga · October 19, 2023

Gainers
Via Benzinga · October 19, 2023

Via Benzinga · October 19, 2023

Via Benzinga · October 2, 2023

Via Benzinga · October 5, 2023

SAB Biotherapeutics (NASDAQ: SABS) has entered into a securities purchase agreement with certain investors to issue and sell shares of preferred stock in a private placement of up to $130 million in gross proceeds.
Via Benzinga · October 2, 2023

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via Benzinga · September 29, 2023